EdgarLookup

MICROCHIP TECHNOLOGY INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that MICROCHIP TECHNOLOGY INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-0%
Profit Margin
Net income ÷ revenue
-0%
Return on Assets
Net income ÷ assets
-3.3%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2019 Mar 31, 2019 $1.33B May 30, 2019
FY2019 Dec 31, 2018 $1.37B May 30, 2019
FY2019 Sep 30, 2018 $1.43B May 30, 2019
FY2019 Jun 30, 2018 $1.21B May 30, 2019
FY2019 Mar 31, 2018 $1.00B May 30, 2019
FY2019 Dec 31, 2017 $994.20M May 30, 2019
FY2019 Sep 30, 2017 $1.01B May 30, 2019
FY2019 Jun 30, 2017 $972.10M May 30, 2019
FY2019 Mar 31, 2017 $3.41B May 30, 2019

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $4.40B May 23, 2025
FY2025 Mar 31, 2024 $7.63B May 23, 2025
FY2025 Mar 31, 2023 $8.44B May 23, 2025
FY2024 Mar 31, 2022 $6.82B May 23, 2024
FY2023 Mar 31, 2021 $5.44B May 25, 2023
FY2020 Mar 31, 2020 $1.33B May 22, 2020
FY2020 Dec 31, 2019 $1.29B May 22, 2020
FY2020 Sep 30, 2019 $1.34B May 22, 2020
FY2020 Jun 30, 2019 $1.32B May 22, 2020
FY2020 Mar 31, 2019 $1.33B May 22, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2018 Mar 31, 2018 $1.00B May 18, 2018
FY2018 Dec 31, 2017 $994.20M May 18, 2018
FY2018 Sep 30, 2017 $1.01B May 18, 2018
FY2018 Jun 30, 2017 $972.10M May 18, 2018
FY2018 Mar 31, 2017 $902.70M May 18, 2018
FY2018 Dec 31, 2016 $834.40M May 18, 2018
FY2018 Sep 30, 2016 $871.40M May 18, 2018
FY2018 Jun 30, 2016 $799.40M May 18, 2018
FY2017 Mar 31, 2016 $557.65M May 30, 2017
FY2017 Dec 31, 2015 $540.34M May 30, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $2.47B May 23, 2025
FY2025 Mar 31, 2024 $5.00B May 23, 2025
FY2025 Mar 31, 2023 $5.70B May 23, 2025
FY2024 Mar 31, 2022 $4.45B May 23, 2024
FY2023 Mar 31, 2021 $3.38B May 25, 2023
FY2020 Mar 31, 2020 $813.90M May 22, 2020
FY2020 Dec 31, 2019 $785.50M May 22, 2020
FY2020 Sep 30, 2019 $827.50M May 22, 2020
FY2020 Jun 30, 2019 $815.20M May 22, 2020
FY2020 Mar 31, 2019 $820.50M May 22, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 ($500.0K) May 23, 2025
FY2025 Mar 31, 2024 $1.91B May 23, 2025
FY2025 Mar 31, 2023 $2.24B May 23, 2025
FY2024 Mar 31, 2022 $1.29B May 23, 2024
FY2023 Mar 31, 2021 $349.40M May 25, 2023
FY2020 Mar 31, 2020 $99.90M May 22, 2020
FY2020 Dec 31, 2019 $311.10M May 22, 2020
FY2020 Sep 30, 2019 $108.90M May 22, 2020
FY2020 Jun 30, 2019 $50.70M May 22, 2020
FY2020 Mar 31, 2019 $174.70M May 22, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $296.30M May 23, 2025
FY2025 Mar 31, 2024 $2.57B May 23, 2025
FY2025 Mar 31, 2023 $3.12B May 23, 2025
FY2024 Mar 31, 2022 $1.85B May 23, 2024
FY2023 Mar 31, 2021 $998.10M May 25, 2023
FY2020 Mar 31, 2020 $160.70M May 22, 2020
FY2020 Dec 31, 2019 $131.20M May 22, 2020
FY2020 Sep 30, 2019 $183.60M May 22, 2020
FY2020 Jun 30, 2019 $171.60M May 22, 2020
FY2020 Mar 31, 2019 $284.60M May 22, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $983.80M May 23, 2025
FY2025 Mar 31, 2024 $1.10B May 23, 2025
FY2025 Mar 31, 2023 $1.12B May 23, 2025
FY2024 Mar 31, 2022 $989.10M May 23, 2024
FY2023 Mar 31, 2021 $836.40M May 25, 2023
FY2022 Mar 31, 2020 $877.80M May 20, 2022
FY2021 Mar 31, 2019 $826.30M May 18, 2021
FY2020 Mar 31, 2018 $529.30M May 22, 2020
FY2019 Mar 31, 2017 $545.30M May 30, 2019
FY2018 Mar 31, 2016 $372.60M May 18, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $617.70M May 23, 2025
FY2025 Mar 31, 2024 $734.20M May 23, 2025
FY2025 Mar 31, 2023 $797.70M May 23, 2025
FY2024 Mar 31, 2022 $718.90M May 23, 2024
FY2023 Mar 31, 2021 $610.30M May 25, 2023
FY2022 Mar 31, 2020 $676.60M May 20, 2022
FY2021 Mar 31, 2019 $682.90M May 18, 2021
FY2020 Mar 31, 2018 $452.10M May 22, 2020
FY2019 Mar 31, 2017 $499.80M May 30, 2019
FY2018 Mar 31, 2016 $301.70M May 18, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $898.10M May 23, 2025
FY2025 Mar 31, 2024 $2.89B May 23, 2025
FY2025 Mar 31, 2023 $3.62B May 23, 2025
FY2024 Mar 31, 2022 $2.84B May 23, 2024
FY2023 Mar 31, 2021 $1.92B May 25, 2023
FY2022 Mar 31, 2020 $1.54B May 20, 2022
FY2021 Mar 31, 2019 $1.67B May 18, 2021
FY2020 Mar 31, 2018 $1.42B May 22, 2020
FY2013 Mar 31, 2013 $459.37M May 30, 2014
FY2013 Mar 31, 2012 $411.98M May 30, 2014

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $126.00M May 23, 2025
FY2025 Mar 31, 2024 $285.10M May 23, 2025
FY2025 Mar 31, 2023 $486.20M May 23, 2025
FY2024 Mar 31, 2022 $370.10M May 23, 2024
FY2023 Mar 31, 2021 $92.60M May 25, 2023
FY2022 Mar 31, 2020 $67.60M May 20, 2022
FY2021 Mar 31, 2019 $228.90M May 18, 2021
FY2020 Mar 31, 2018 $206.80M May 22, 2020

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $15.37B May 23, 2025
FY2025 Mar 31, 2024 $15.87B May 23, 2025
FY2024 Mar 31, 2023 $16.37B May 23, 2024
FY2023 Mar 31, 2022 $16.20B May 25, 2023
FY2022 Mar 31, 2021 $16.48B May 20, 2022
FY2021 Mar 31, 2020 $17.43B May 18, 2021
FY2020 Mar 31, 2019 $18.35B May 22, 2020
FY2019 Mar 31, 2018 $8.26B May 30, 2019
FY2018 Mar 31, 2017 $7.69B May 18, 2018
FY2017 Mar 31, 2016 $5.54B May 30, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $7.08B May 23, 2025
FY2025 Mar 31, 2024 $6.66B May 23, 2025
FY2025 Mar 31, 2023 $6.51B May 23, 2025
FY2025 Mar 31, 2022 $5.89B May 23, 2025
FY2024 Mar 31, 2021 $5.34B May 23, 2024
FY2023 Mar 31, 2020 $5.59B May 25, 2023
FY2022 Mar 31, 2019 $5.29B May 20, 2022
FY2021 Mar 31, 2018 $3.28B May 18, 2021
FY2020 Mar 31, 2017 $3.27B May 22, 2020
FY2017 Mar 31, 2016 ($3.36M) May 30, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $6.68B May 23, 2025
FY2025 Mar 31, 2024 $6.68B May 23, 2025
FY2024 Mar 31, 2023 $6.67B May 23, 2024
FY2023 Mar 31, 2022 $6.67B May 25, 2023
FY2022 Mar 31, 2021 $6.67B May 20, 2022
FY2021 Mar 31, 2020 $6.66B May 18, 2021
FY2020 Mar 31, 2019 $6.66B May 22, 2020
FY2019 Mar 31, 2018 $2.30B May 30, 2019
FY2018 Mar 31, 2017 $2.30B May 18, 2018
FY2017 Mar 31, 2016 $1.01B May 30, 2017

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $5.78B May 23, 2025
FY2025 Mar 31, 2024 $6.76B May 23, 2025
FY2024 Mar 31, 2023 $5.76B May 23, 2024
FY2023 Mar 31, 2022 $4.18B May 25, 2023
FY2022 Mar 31, 2021 $3.39B May 20, 2022
FY2021 Mar 31, 2020 $3.43B May 18, 2021
FY2020 Mar 31, 2019 $3.21B May 22, 2020
FY2019 Apr 1, 2018 $3.20B May 30, 2019
FY2019 Mar 31, 2018 $1.40B May 30, 2019
FY2018 Mar 31, 2017 $1.48B May 18, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $771.70M May 23, 2025
FY2025 Mar 31, 2024 $319.70M May 23, 2025
FY2024 Mar 31, 2023 $234.00M May 23, 2024
FY2023 Mar 31, 2022 $317.40M May 25, 2023
FY2022 Mar 31, 2021 $280.00M May 20, 2022
FY2021 Mar 31, 2020 $401.00M May 18, 2021
FY2020 Mar 31, 2019 $428.60M May 22, 2020
FY2019 Mar 31, 2018 $901.30M May 30, 2019
FY2018 Mar 31, 2017 $908.70M May 18, 2018
FY2018 Mar 31, 2016 $2.09B May 18, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $5.63B May 23, 2025
FY2025 Mar 31, 2024 $6.00B May 23, 2025
FY2024 Mar 31, 2023 $6.44B May 23, 2024
FY2023 Mar 31, 2022 $7.69B May 25, 2023
FY2022 Mar 31, 2021 $8.90B May 20, 2022
FY2021 Mar 31, 2020 $9.48B May 18, 2021
FY2020 Mar 31, 2019 $10.31B May 22, 2020
FY2019 Mar 31, 2018 $3.07B May 30, 2019
FY2018 Mar 31, 2017 $2.95B May 18, 2018
FY2017 Mar 31, 2016 $2.45B May 30, 2017

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 0 May 23, 2025
FY2025 Mar 31, 2024 3 May 23, 2025
FY2025 Mar 31, 2023 4 May 23, 2025
FY2024 Mar 31, 2022 2 May 23, 2024
FY2023 Mar 31, 2021 0 May 25, 2023
FY2022 Mar 31, 2020 1 May 20, 2022
FY2021 Mar 31, 2019 1 May 18, 2021
FY2020 Mar 31, 2018 1 May 22, 2020
FY2019 Mar 31, 2017 0 May 30, 2019
FY2018 Mar 31, 2016 1 May 18, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 0 May 23, 2025
FY2025 Mar 31, 2024 3 May 23, 2025
FY2025 Mar 31, 2023 4 May 23, 2025
FY2024 Mar 31, 2022 2 May 23, 2024
FY2023 Mar 31, 2021 0 May 25, 2023
FY2020 Mar 31, 2020 0 May 22, 2020
FY2020 Dec 31, 2019 1 May 22, 2020
FY2020 Sep 30, 2019 0 May 22, 2020
FY2020 Jun 30, 2019 0 May 22, 2020
FY2020 Mar 31, 2019 0 May 22, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 538.70M May 23, 2025
FY2025 Mar 31, 2024 536.66M May 23, 2025
FY2024 Mar 31, 2023 545.46M May 23, 2024
FY2023 Mar 31, 2022 554.50M May 25, 2023
FY2022 Mar 31, 2021 547.06M May 20, 2022
FY2021 Mar 31, 2020 245.33M May 18, 2021
FY2020 Mar 31, 2019 237.59M May 22, 2020
FY2019 Mar 31, 2018 235.03M May 30, 2019
FY2018 Mar 31, 2017 229.09M May 18, 2018
FY2017 Mar 31, 2016 204.08M May 30, 2017